DARE-19 Phase III Collaboration between AstraZeneca, Saint Luke’s Mid America Heart Institute and George Clinical Shows Treatment’s Well-Established Safety Profile Was Consistent in Patients with COVID-19
OVERLAND PARK, KS, July 29, 2021 (GLOBE NEWSWIRE) — The findings of DARE-19, a double-blind, placebo-controlled Phase III trial examining